Intervention Protocol

Angiotensin converting enzyme inhibitors for heart failure

  1. John GF Cleland1,*,
  2. Nick Freemantle2,
  3. Joanne Eastaugh3,
  4. Martin Eccles4,
  5. James Mason5,
  6. Jane Harrison3

Editorial Group: Cochrane Heart Group

Published Online: 21 JAN 2009

DOI: 10.1002/14651858.CD002134

Database Title

Additional Information

How to Cite

Cleland JGF, Freemantle N, Eastaugh J, Eccles M, Mason J, Harrison J. Angiotensin converting enzyme inhibitors for heart failure (Protocol). Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD002134. DOI: 10.1002/14651858.CD002134.

Author Information

  1. 1

    Castle Hill Hospital, Academic Unit of Cardiology, East Yorkshire, UK

  2. 2

    University of Birmingham, Department of Primary Care and General Practice, Birmingham, UK

  3. 3

    University of York, Medicines Evaluation Group, Centre for Health, York, UK

  4. 4

    Newcastle University, Institute of Health & Society, Newcastle-upon-Tyne, Tyne and Wear, UK

  5. 5

    Durham University, Queen's Campus, School of Medicine and Health, Stockton-on-Tees, UK

*John GF Cleland, Academic Unit of Cardiology, Castle Hill Hospital, Castle Road, Cottingham, East Yorkshire, HU16 5JQ, UK. j.g.cleland@hull.ac.uk. j.g.cleland@medschool.hull.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Full (83K)
 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Our objective is to appraise the effectiveness of ACEi in patients with heart failure. Our protocol defined main outcome is all cause mortality. The specific a priori defined aims are to examine: the effectiveness of ACEi in patients with heart failure; the extent to which the choice of drug may affect outcome; the magnitude of benefits achieved by ACE inhibitors and their clinical importance.

View Full Article (HTML) Full (83K)